Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Alzheimer’s Association International Conference (AAIC) - Allele Capital

https://ir.coyatherapeutics.com/news/news-details/2023/Coya-Therapeutics-to-Present-Proof-of-Concept-Clinical-Data-for-Low-Dose-Interleukin-2-ld-IL-2-for-the-Treatment-of-Patients-with-Alzheimers-Disease-AD-at-the-2023-Alzheimers-Association-International-Conference-AAIC/default.aspx